The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Etifoxine for Pain Patients with Anxiety

  • Choi, Yun Mi (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University) ;
  • Kim, Kyung Hoon (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University)
  • Received : 2014.12.16
  • Accepted : 2014.12.18
  • Published : 2015.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Etifoxine (etafenoxine, $Stresam^{(R)}$) is a non-benzodiazepine anxiolytic with an anticonvulsant effect. It was developed in the 1960s for anxiety disorders and is currently being studied for its ability to promote peripheral nerve healing and to treat chemotherapy-induced pain. In addition to being mediated by $GABA_A{\alpha}2$ receptors like benzodiazepines, etifoxine appears to produce anxiolytic effects directly by binding to ${\beta}2$ or ${\beta}3$ subunits of the $GABA_A$ receptor complex. It also modulates $GABA_A$ receptors indirectly via stimulation of neurosteroid production after etifoxine binds to the 18 kDa translocator protein (TSPO) of the outer mitochondrial membrane in the central and peripheral nervous systems, previously known as the peripheral benzodiazepine receptor (PBR). Therefore, the effects of etifoxine are not completely reversed by the benzodiazepine antagonist flumazenil. Etifoxine is used for various emotional and bodily reactions followed by anxiety. It is contraindicated in situations such as shock, severely impaired liver or kidney function, and severe respiratory failure. The average dosage is 150 mg per day for no more than 12 weeks. The most common adverse effect is drowsiness at the initial stage. It does not usually cause any withdrawal syndromes. In conclusion, etifoxine shows less adverse effects of anterograde amnesia, sedation, impaired psychomotor performance, and withdrawal syndromes than those of benzodiazepines. It potentiates $GABA_A$ receptor-function by a direct allosteric effect and by an indirect mechanism involving the activation of TSPO. It seems promising that non-benzodiazepine anxiolytics including etifoxine will replenish shortcomings of benzodiazepines and selective serotonin reuptake inhibitors according to animated studies related to TSPO.

Keywords

References

  1. Means-Christensen AJ, Roy-Byrne PP, Sherbourne CD, Craske MG, Stein MB. Relationships among pain, anxiety, and depression in primary care. Depress Anxiety 2008; 25: 593-600. https://doi.org/10.1002/da.20342
  2. Farb DH, Ratner MH. Targeting the modulation of neural circuitry for the treatment of anxiety disorders. Pharmacol Rev 2014; 66: 1002-32. https://doi.org/10.1124/pr.114.009126
  3. Almeida TF, Roizenblatt S, Tufik S. Afferent pain pathways: a neuroanatomical review. Brain Res 2004; 1000: 40-56. https://doi.org/10.1016/j.brainres.2003.10.073
  4. Willis WD, Westlund KN. Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol 1997; 14: 2-31. https://doi.org/10.1097/00004691-199701000-00002
  5. Price DD. Central neural mechanisms that interrelate sensory and affective dimensions of pain. Mol Interv 2002; 2: 392-403, 339. https://doi.org/10.1124/mi.2.6.392
  6. Price DD. Psychological and neural mechanisms of the affective dimension of pain. Science 2000; 288: 1769-72. https://doi.org/10.1126/science.288.5472.1769
  7. Rainville P, Duncan GH, Price DD, Carrier B, Bushnell MC. Pain affect encoded in human anterior cingulate but not somatosensory cortex. Science 1997; 277: 968-71. https://doi.org/10.1126/science.277.5328.968
  8. Hamon A, Morel A, Hue B, Verleye M, Gillardin JM. The modulatory effects of the anxiolytic etifoxine on GABA(A) receptors are mediated by the beta subunit. Neuropharmacology 2003; 45: 293-303. https://doi.org/10.1016/S0028-3908(03)00187-4
  9. Schlichter R, Rybalchenko V, Poisbeau P, Verleye M, Gillardin J. Modulation of GABAergic synaptic transmission by the non-benzodiazepine anxiolytic etifoxine. Neuropharmacology 2000; 39: 1523-35. https://doi.org/10.1016/S0028-3908(99)00253-1
  10. Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapere JJ, Lindemann P, et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006; 27: 402-9. https://doi.org/10.1016/j.tips.2006.06.005
  11. Zeilhofer HU. Etifoxine (Stresam) for chemotherapy-induced pain? Pain 2009; 147: 9-10. https://doi.org/10.1016/j.pain.2009.09.021
  12. Kucken AM, Wagner DA, Ward PR, Teissere JA, Boileau AJ, Czajkowski C. Identification of benzodiazepine binding site residues in the gamma2 subunit of the gamma-aminobutyric acid(A) receptor. Mol Pharmacol 2000; 57: 932-9.
  13. Sigel E, Steinmann ME. Structure, function, and modulation of GABA(A) receptors. J Biol Chem 2012; 287: 40224-31. https://doi.org/10.1074/jbc.R112.386664
  14. Scheller M, Forman SA. The gamma subunit determines whether anesthetic-induced leftward shift is altered by a mutation at alpha1S270 in alpha1beta2gamma2L GABA(A) receptors. Anesthesiology 2001; 95: 123-31. https://doi.org/10.1097/00000542-200107000-00022
  15. Olsen RW, Li GD. GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth 2011; 58: 206-15. https://doi.org/10.1007/s12630-010-9429-7
  16. Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 2010; 9: 971-88. https://doi.org/10.1038/nrd3295
  17. Gunn BG, Brown AR, Lambert JJ, Belelli D. Neurosteroids and GABA(A) receptor interactions: a focus on stress. Front Neurosci 2011; 5: 131.
  18. Girard C, Liu S, Cadepond F, Adams D, Lacroix C, Verleye M, et al. Etifoxine improves peripheral nerve regeneration and functional recovery. Proc Natl Acad Sci U S A 2008; 105: 20505-10. https://doi.org/10.1073/pnas.0811201106
  19. Girard C, Liu S, Adams D, Lacroix C, Sineus M, Boucher C, et al. Axonal regeneration and neuroinflammation: roles for the translocator protein 18 kDa. J Neuroendocrinol 2012; 24: 71-81. https://doi.org/10.1111/j.1365-2826.2011.02215.x
  20. Zhou X, He X, He B, Zhu Z, Zheng C, Xu J, et al. Etifoxine promotes glial-derived neurotrophic factor-induced neurite outgrowth in PC12 cells. Mol Med Rep 2013; 8: 75-80. https://doi.org/10.3892/mmr.2013.1474
  21. Dai T, Zhou X, Li Y, He B, Zhu Z, Zheng C, et al. Etifoxine promotes glia-derived neurite outgrowth in vitro and in vivo. J Reconstr Microsurg 2014; 30: 381-8. https://doi.org/10.1055/s-0034-1381751
  22. Zhou X, He B, Zhu Z, He X, Zheng C, Xu J, et al. Etifoxine provides benefits in nerve repair with acellular nerve grafts. Muscle Nerve 2014; 50: 235-43. https://doi.org/10.1002/mus.24131
  23. Daugherty DJ, Selvaraj V, Chechneva OV, Liu XB, Pleasure DE, Deng W. A TSPO ligand is protective in a mouse model of multiple sclerosis. EMBO Mol Med 2013; 5: 891-903. https://doi.org/10.1002/emmm.201202124
  24. Aouad M, Charlet A, Rodeau JL, Poisbeau P. Reduction and prevention of vincristine-induced neuropathic pain symptoms by the non-benzodiazepine anxiolytic etifoxine are mediated by 3alpha-reduced neurosteroids. Pain 2009; 147: 54-9. https://doi.org/10.1016/j.pain.2009.08.001
  25. Aouad M, Petit-Demouliere N, Goumon Y, Poisbeau P. Etifoxine stimulates allopregnanolone synthesis in the spinal cord to produce analgesia in experimental mononeuropathy. Eur J Pain 2014; 18: 258-68. https://doi.org/10.1002/j.1532-2149.2013.00367.x
  26. Aouad M, Zell V, Juif PE, Lacaud A, Goumon Y, Darbon P, et al. Etifoxine analgesia in experimental monoarthritis: a combined action that protects spinal inhibition and limits central inflammatory processes. Pain 2014;155:403-12. https://doi.org/10.1016/j.pain.2013.11.003
  27. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-5. https://doi.org/10.1111/j.2044-8341.1959.tb00467.x
  28. McCracken LM, Zayfert C, Gross RT. The Pain Anxiety Symptoms Scale: development and validation of a scale to measure fear of pain. Pain 1992; 50: 67-73. https://doi.org/10.1016/0304-3959(92)90113-P
  29. McCracken LM, Dhingra L. A short version of the Pain Anxiety Symptoms Scale (PASS-20): preliminary development and validity. Pain Res Manag 2002; 7: 45-50. https://doi.org/10.1155/2002/517163
  30. Micallef J, Soubrouillard C, Guet F, Le Guern ME, Alquier C, Bruguerolle B, et al. A double blind parallel group placebo controlled comparison of sedative and mnesic effects of etifoxine and lorazepam in healthy subjects [corrected]. Fundam Clin Pharmacol 2001; 15: 209-16. https://doi.org/10.1046/j.1472-8206.2001.00025.x
  31. Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, et al. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol 2006; 21: 139-49. https://doi.org/10.1002/hup.757
  32. Verleye M, Gillardin JM. Effects of etifoxine on stress-induced hyperthermia, freezing behavior and colonic motor activation in rats. Physiol Behav 2004; 82: 891-7. https://doi.org/10.1016/S0031-9384(04)00313-0
  33. Moch C, Rocher F, Laine P, Lacotte J, Biour M, Gouraud A, et al. Etifoxine-induced acute hepatitis: a case series. Clin Res Hepatol Gastroenterol 2012; 36: e85-8. https://doi.org/10.1016/j.clinre.2012.04.002
  34. Nadendla LK, Meduri V, Paramkusam G, Pachava KR. Evaluation of salivary cortisol and anxiety levels in myofascial pain dysfunction syndrome. Korean J Pain 2014; 27: 30-4. https://doi.org/10.3344/kjp.2014.27.1.30
  35. Cho SK, Heiby EM, McCracken LM, Moon DE, Lee JH. Daily functioning in chronic pain: study of structural relations with posttraumatic stress disorder symptoms, pain intensity, and pain avoidance. Korean J Pain 2011; 24: 13-21. https://doi.org/10.3344/kjp.2011.24.1.13

Cited by

  1. Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics vol.125, pp.5, 2017, https://doi.org/10.1213/ANE.0000000000002442
  2. Comparative evaluation of the effect of remifentanil and 2 different doses of esmolol on pain during propofol injection vol.96, pp.10, 2017, https://doi.org/10.1097/MD.0000000000006288
  3. Anxiolytic-like effects of α-asarone in a mouse model of chronic pain pp.1573-7365, 2017, https://doi.org/10.1007/s11011-017-0108-z
  4. Could a blood test for PTSD and depression be on the horizon? vol.15, pp.12, 2018, https://doi.org/10.1080/14789450.2018.1544894
  5. TSPO Ligands Promote Cholesterol Efflux and Suppress Oxidative Stress and Inflammation in Choroidal Endothelial Cells vol.19, pp.12, 2018, https://doi.org/10.3390/ijms19123740
  6. receptors: Insights on etifoxine vol.19, pp.sup1, 2018, https://doi.org/10.1080/15622975.2018.1468030
  7. Sleep disorders (insomnia) as a psychoneurological dilemma in the diagnosis and treatment vol.116, pp.11, 2015, https://doi.org/10.17116/jnevro201611611218-23
  8. Etifoxine, a TSPO Ligand, Worsens Hepatitis C-Related Insulin Resistance but Relieves Lipid Accumulation vol.2019, pp.None, 2015, https://doi.org/10.1155/2019/3102414
  9. An updated review on pathophysiology and management of burning mouth syndrome with endocrinological, psychological and neuropathic perspectives vol.46, pp.6, 2015, https://doi.org/10.1111/joor.12795
  10. Diastereoselective synthesis of CF3-oxazinoquinolines in water vol.21, pp.23, 2015, https://doi.org/10.1039/c9gc03044a
  11. Scopoletin ameliorates anxiety-like behaviors in complete Freund’s adjuvant-induced mouse model vol.13, pp.1, 2015, https://doi.org/10.1186/s13041-020-0560-2